Norman Lepor, MD
Cardiology · Beverly Hills, CANPI 1013979673
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,438,137 of the $1,883,993 with a category attached, or 76.3%. It is spread thinly across 56 manufacturers, the largest accounting for just 12.7%. Reporting peaked in 2019 at $493,260 and has fallen 65.3% since, to $171,228 in 2025. Among cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,346 payments — averaging $803.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$238K
- Lilly USA, LLC$201K
- Merck$192K
- Bayer$178K
- Sanofi-aventis U.S. LLC$157K
- Novo Nordisk$133K
- plus $784K from 50 others
Across 539 payments — averaging $9997.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Amgen$1.1M
- AstraZeneca$595K
- Eli Lilly$529K
- Regeneron$262K
- Bayer$201K
- plus $1.1M from 14 others
What the payments were for
- Consulting fees$212,33911%
- Speaking & faculty fees$1,438,13776%
- Travel & lodging$180,61810%
- Food & beverage$52,7573%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,883,993 in reported general payments places this provider in the 95th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 185 | $239,283 |
| EliquisApixaban | 201 | $217,598 |
| Repatha SureclickEvolocumab | 173 | $148,524 |
| FarxigaDapagliflozin Propanediol | 111 | $114,544 |
| VascepaIcosapent Ethyl | 173 | $105,251 |
| TrulicityDulaglutide | 39 | $60,754 |
| EntrestoSacubitril/Valsartan | 51 | $60,647 |
| XareltoRivaroxaban | 50 | $58,592 |
| Praluent PenAlirocumab | 67 | $58,286 |
| KerendiaFinerenone | 31 | $38,030 |
| MultaqDronedarone Hcl | 24 | $34,072 |
| MounjaroTirzepatide | 21 | $31,520 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 61 | $25,143 |
| InpefaSotagliflozin | 26 | $23,292 |
| OzempicSemaglutide | 20 | $20,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa | $238,493 | $252,113221 claims |
| PfizerEliquis | $1,059 | $217,598201 claims |
| AstraZenecaFarxiga | $94,518 | $114,544111 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $201,040 | $92,27460 claims |
| NovartisEntresto | $89,122 | $60,64751 claims |
| Johnson & JohnsonXarelto | $729 | $58,59250 claims |
| BayerKerendia | $178,255 | $38,03031 claims |
| Novo NordiskOzempic, Wegovy | $132,588 | $35,45131 claims |
| Sanofi-aventis U.S. LLCMultaq | $157,205 | $34,07224 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $107,309 | $28,49542 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $119 | $25,14361 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $51,909 | $23,29226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 cardiology providers in California.
Other cardiology in Beverly Hills
- Shahram RavanBeverly Hills$4K
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
- Bipin JoshiFresno$51K
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Hooman MadyoonLos Angeles$24K
- Lakhjit SandhuFresno$19K
- Prabhtej BraraSanta Monica$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.